Literature DB >> 10757340

Theories of endometrial carcinogenesis: a multidisciplinary approach.

M E Sherman1.   

Abstract

Historical observations have suggested that endometrial carcinomas vary in histopathologic appearance and clinical features. More recent, systematic studies have provided epidemiologic, clinicopathologic, and molecular support for these observations. Specifically, studies suggest that the most common type of endometrial carcinoma, endometrioid adenocarcinoma, develops from endometrial hyperplasia in the setting of excess estrogen exposure and usually pursues an indolent clinical course. In contrast, a minority of endometrial carcinomas, best represented by serous carcinoma, do not seem to be related to estrogenic risk factors or elevated serum hormone levels, and these tumors seem to develop from atrophic rather than hyperplastic epithelium. We have proposed that serous carcinomas develop from "endometrial intraepithelial carcinoma," a lesion representing malignant transformation of the endometrial surface epithelium. Whereas endometrioid carcinoma and endometrial hyperplasia are associated with microsatellite instability and ras and PTEN mutations, serous carcinoma and endometrial intraepithelial carcinoma are associated with p53 mutations and abnormal accumulation of p53 protein. Based on these data regarding the pathogenesis of endometrioid and serous carcinoma, we have proposed a dualistic model of endometrial carcinogenesis incorporating a "classic" estrogen-driven pathway and an "alternative" pathway seemingly unrelated to hormones. It is hoped that further studies may permit the extension and modification of this model and that these advances will lead to improved diagnosis, management, and prevention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757340     DOI: 10.1038/modpathol.3880051

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  99 in total

1.  High levels of Nrf2 determine chemoresistance in type II endometrial cancer.

Authors:  Tao Jiang; Ning Chen; Fei Zhao; Xiao-Jun Wang; Beihua Kong; Wenxin Zheng; Donna D Zhang
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

Review 3.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

4.  The occurrence of fetal microchimeric cells in endometrial tissues is a very common phenomenon in benign uterine disorders, and the lower prevalence of fetal microchimerism is associated with better uterine cancer prognoses.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Petra Pirkova; Pavla Libalova; Zdenka Vernerova; Bohuslav Svoboda; Eduard Kucera
Journal:  DNA Cell Biol       Date:  2013-11-27       Impact factor: 3.311

5.  PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.

Authors:  F Kimura; J Watanabe; H Hata; T Fujisawa; Y Kamata; Y Nishimura; T Jobo; H Kuramoto
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-20       Impact factor: 4.553

Review 6.  Management of endometrial precancers.

Authors:  Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

7.  The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.

Authors:  Paul A Foster; L W Lawrence Woo; Barry V L Potter; Michael J Reed; Atul Purohit
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 8.  [Precursor lesions of endometrial carcinoma].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

9.  Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women.

Authors:  Louise A Brinton; Britton Trabert; Garnet L Anderson; Roni T Falk; Ashley S Felix; Barbara J Fuhrman; Margery L Gass; Lewis H Kuller; Ruth M Pfeiffer; Thomas E Rohan; Howard D Strickler; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-12       Impact factor: 4.254

10.  Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer.

Authors:  L M Berstein; J O Kvatchevskaya; T E Poroshina; I G Kovalenko; E V Tsyrlina; T S Zimarina; A F Ourmantcheeva; L Ashrafian; J H H Thijssen
Journal:  J Cancer Res Clin Oncol       Date:  2004-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.